Volume 23 Issue 11
Nov.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(11): 1818-1824
ZHA Daogang, WU Pingsheng. Key points interpretation of the latest European guidelines for dyslipidemia management in 2025[J]. Chinese Journal of General Practice, 2025, 23(11): 1818-1824. doi: 10.16766/j.cnki.issn.1674-4152.004236
Citation: ZHA Daogang, WU Pingsheng. Key points interpretation of the latest European guidelines for dyslipidemia management in 2025[J]. Chinese Journal of General Practice, 2025, 23(11): 1818-1824. doi: 10.16766/j.cnki.issn.1674-4152.004236
shu

Key points interpretation of the latest European guidelines for dyslipidemia management in 2025

doi: 10.16766/j.cnki.issn.1674-4152.004236

  • Department of General Practice, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China

  • Received Date: 2025-09-18
    Available Online: 2026-01-07
    Abstract
  • Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among urban and rural residents in China, and hyperlipidemia is one of the key risk factors for ASCVD. It is therefore of great significance to master the latest guidelines for the management of dyslipidemia. In 2025, the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) released "2025 Focused update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias". The main contents include: recommending the use of SCORE2 and SCORE2-OP to replace the traditional SCORE model for cardiovascular risk assessment, emphasizing the importance of individualized consideration of risk-enhancing factors; recommending novel lipid-lowering drugs for patients with statin intolerance or suboptimal efficacy; advocating early intensive combined lipid-lowering therapy in hospitalized patients with acute coronary syndrome; suggesting that adults should undergo at least one Lp(a) measurement, especially high-risk individuals; considering high-purity icosapent ethyl for patients with hypertriglyceridemia; recommending the use of statins for primary prevention in HIV-infected individuals aged ≥40 years; considering statin use in cancer patients at high risk of chemotherapy-related cardiovascular toxicity; and not recommending dietary supplements without proven benefit for lipid lowering. This article aims to interpret the key updates, with the goal of assisting general practitioners in better understanding the new recommendations and optimizing lipid management strategies in clinical practice.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    MACH F, KOSKINAS K C, ROETERS VAN LENNEP J E, et al. 2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)[J/OL]. Eur Heart J, 2025: ehaf190. DOI: 10.1093/eurheartj/ehaf190.
    [2]
    SCORE2 working group and ESC cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe[J]. Eur Heart J, 2021, 42(25): 2439-2454. doi: 10.1093/eurheartj/ehab309
    [3]
    SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions[J]. Eur Heart J, 2021, 42(25): 2455-2467. doi: 10.1093/eurheartj/ehab312
    [4]
    CONROY R M, PYÖRǍLǍ K, FITZGERALD A P, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project[J]. Eur Heart J, 2003, 24(11): 987-1003. doi: 10.1016/S0195-668X(03)00114-3
    [5]
    LIU J, SEMPOS C T, DONAHUE R P, et al. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease[J]. Am J Cardiol, 2006, 98(10): 1363-1368. doi: 10.1016/j.amjcard.2006.06.032
    [6]
    FERENCE B A, GINSBERG H N, GRAHAM I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J, 2017, 38(32): 2459-2472. doi: 10.1093/eurheartj/ehx144
    [7]
    MACH F, BAIGENT C, CATAPANO A L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)[J]. Eur Heart J, 2020, 41(1): 111-188. doi: 10.1093/eurheartj/ehz455
    [8]
    VISSEREN F L J, MACH F, SMULDERS Y M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice: Developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC)[J]. Eur Heart J, 2021, 42(34): 3227-3337. doi: 10.1093/eurheartj/ehab484
    [9]
    RUSCICA M, SIRTORI C R, CARUGO S, et al. Bempedoic acid: for whom and when[J]. Curr Atheroscler Rep, 2022, 24(10): 791-801. doi: 10.1007/s11883-022-01054-2
    [10]
    NISSEN S E, LINCOFF A M, BRENNAN D, et al. Bempedoic Acid and cardiovascular outcomes in statin-intolerant patients[J]. N Engl J Med, 2023, 388(15): 1353-1364. doi: 10.1056/NEJMoa2215024
    [11]
    RAY K K, NICHOLLS S J, LI N, et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial[J]. Lancet Diabetes Endocrinol, 2024, 12(1): 19-28. doi: 10.1016/S2213-8587(23)00316-9
    [12]
    HPS-4/TIMI 65/ORION-4: a double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease[DS/OL]. (2018-10-10)[2025-10-13]. https://clinicaltrials.gov/study/NCT03705234.
    [13]
    A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)[DS/OL]. (2021-08-17)[2025-10-13]. https://clinicaltrials.gov/study/NCT05030428.
    [14]
    RAAL F J, ROSENSON R S, REESKAMP L F, et al. Evinacumab for homozygous familial hypercholesterolemia[J]. N Engl J Med, 2020, 383(8): 711-720. doi: 10.1056/NEJMoa2004215
    [15]
    XIE X, SHI X, ZHANG Y, et al. Angiopoietin-Like 3 antibody therapy in patients with suboptimally controlled hyperlipidemia: a phase 2 study[J]. J Am Coll Cardiol, 2025, 85(19): 1821-1835. doi: 10.1016/j.jacc.2025.03.008
    [16]
    DE LEMOS J A, BLAZING M A, WIVIOTT S D, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes phase Z of the A to Z trial[J]. JAMA, 2004, 292(11): 1307-1316. doi: 10.1001/jama.292.11.1307
    [17]
    RAY K K, CANNON C P, MCCABE C H, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes[J]. JACC, 2005, 46(8): 1405-1410. doi: 10.1016/j.jacc.2005.03.077
    [18]
    JERNBERG T, HASVOLD P, HENRIKSSON M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective[J]. Eur Heart J, 2015, 36(19): 1163-1170. doi: 10.1093/eurheartj/ehu505
    [19]
    STEEN D L, KHAN I, ANDRADE K, et al. Event rates and risk factors for recurrent cardiovascular events and mortality in a contemporary post acute coronary syndrome population representing 239234 patients during 2005 to 2018 in the United States[J/OL]. J Am Heart Assoc, 2022, 11(9): e022198. DOI: 10.1161/JAHA.121.022198.
    [20]
    CANNON C P, BLAZING M A, GIUGLIANO R P, et al. Ezetimibe added to statin therapy after acute coronary syndromes[J]. N Engl J Med, 2015, 372(25): 2387-2397. doi: 10.1056/NEJMoa1410489
    [21]
    NICHOLLS S J, KATAOKA Y, NISSEN S E, et al. Effect of Evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction[J]. JACC Cardiovasc Imaging, 2022, 15(7): 1308-1321. doi: 10.1016/j.jcmg.2022.03.002
    [22]
    BABER L, UEKI Y, OTSUKA T, et al. Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial[J]. JAMA, 2022, 327(18): 1771-1781. doi: 10.1001/jama.2022.5218
    [23]
    MAKHMUDOVA U, SAMADIFAR B, MALOKU A, et al. Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction("Jena auf Ziel")[J]. Clin Res Cardiol, 2023, 112(9): 1212-1219. doi: 10.1007/s00392-022-02147-3
    [24]
    KOSKINAS K C, WINDECKER S, PEDRAZZINI G, et al. Evolocumab for early reduction of ldl cholesterol levels in patients with acute coronary syndromes (EVOPACS)[J]. JACC, 2019, 74(20): 2452-2462. doi: 10.1016/j.jacc.2019.08.010
    [25]
    LEUCKER T M, BLAHA M J, JONES S R, et al. Effect of Evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period[J]. Circulation, 2020, 142(4): 419-421. doi: 10.1161/CIRCULATIONAHA.120.046320
    [26]
    KRONENBERG F, MORA S, STROES E S G, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement[J]. Eur Heart J, 2022, 43(39): 3925-3946. doi: 10.1093/eurheartj/ehac361
    [27]
    KAMSTRUP P R, TYBJÆRG-HANSEN A, NORDESTGAARD B G. Extreme Lipoprotein(a) levels and improved cardiovascular risk prediction[J]. JACC, 2013, 61(11): 1146-1156. doi: 10.1016/j.jacc.2012.12.023
    [28]
    PRADHAN A D, GLYNN R J, FRUCHART J, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk[J]. N Engl J Med, 2022, 387(21): 1923-1934. doi: 10.1056/NEJMoa2210645
    [29]
    NICHOLLS S J, LINCOFF A M, GARCIA M, et al. Effect of high-dose Omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial[J]. JAMA, 2020, 324(22): 2268-2280. doi: 10.1001/jama.2020.22258
    [30]
    BHATT D L, STEG P G, MILLER M, et al. Cardiovascular risk reduction with Icosapent Ethyl for hypertriglyceridemia[J]. N Engl J Med, 2019, 380(1): 11-22. doi: 10.1056/NEJMoa1812792
    [31]
    SHAH A S V, STELZLE D, LEE K K, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis[J]. Circulation, 2018, 138: 1100-1112. doi: 10.1161/CIRCULATIONAHA.117.033369
    [32]
    GRINSPOON S K, FITCH K V, ZANNI M V, et al. Pitavastatin to prevent cardiovascular disease in HIV infection[J]. N Engl J Med, 2023, 389(8): 687-699. doi: 10.1056/NEJMoa2304146
    [33]
    NEILAN T G, QUINAGLIA T, ONOUE T, et al. Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial[J]. JAMA, 2023, 330(6): 528-536. doi: 10.1001/jama.2023.11887
    [34]
    D'AMARIO D, LABORANTE R, BIANCHINI E, et al. Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials[J]. Int J of Cardiol, 2023, 391: 131219. DOI: 10.1016/j.ijcard.2023.131219.
    [35]
    FELIX N, NOGUEIRA P C, SILVA I M, et al. Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: an updated meta-analysis of randomized controlled trials[J]. Eur J Intern Med, 2024, 126: 43-48. doi: 10.1016/j.ejim.2024.04.007
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (101) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return